Document:

SEC Connect

 

Exhibit
10.1

WAIVER

This waiver (this “Waiver”)
is granted as of February [21], 2017, by Platinum-Montaur Life Sciences, LLC, a
Delaware limited liability company (“Platinum
Montaur”) in favor of
FluoroPharma Medical, Inc., a Nevada corporation (the
“Company”).
Capitalized terms used but not defined herein shall have the
meaning given to such term in the Purchase Agreement and the
Warrant (each, as defined below), as
applicable.

RECITALS

WHEREAS, pursuant to that certain
Securities Purchase Agreement, dated as of September 18, 2013, by
and between Platinum Montaur and the Company (the
“Purchase
Agreement”) and that certain Common Stock Purchase
Warrant, dated as of September 18, 2013, granted by the Company in
favor of Platinum Montaur (the “Warrant”), Platinum
Montaur purchased [4,523,076] Preferred Shares and Warrants to
purchase [6,020,214] shares of the Company’s common
stock;

WHEREAS, pursuant to Section 3.11(c) of
the Purchase Agreement, for so long as not less than 25% of the
Preferred Shares issued pursuant to the Purchase Agreement remain
outstanding, if the Company enters into any Subsequent Financing on
terms more favorable than the terms governing the sale of the
Preferred Stock thereunder, as determined by Platinum Montaur in
its reasonable discretion, then Platinum Montaur in its sole
discretion may exchange the Preferred Shares then held by it,
valued at their stated value, together with accrued but unpaid
dividends, for the securities issued or to be issued in the
Subsequent Financing (the “Preferred Ratchet
Rights”);

WHEREAS, pursuant to Section 3(e) of the
Warrant, during the term of the Warrant, in the event the Company
shall issue any Additional Shares of Common Stock or Convertible
Securities, other than as provided in Sections 3(a) through 3(d),
at a price per share less than the Exercise Price then in effect or
without consideration, then the Exercise Price upon each such
issuance shall be adjusted to the price equal to the consideration
per share paid for such Additional Shares of Common Stock or
Convertible Securities (the “Warrant Ratchet
Rights”);

WHEREAS, on February 10, 2017, the
Company provided notice to Platinum Montaur of its intent to
effectuate a Subsequent Financing, on terms more favorable than the
terms governing the sale of the Preferred Stock under the Purchase
Agreement, pursuant to which it may issue Additional Shares of
Common Stock or Convertible Securities at a price per share less
than the Exercise Price in the Warrant (the “Subsequent Financing”);
and

WHEREAS, the Company wishes that
Platinum Montaur waive, and Platinum Montaur is willing to waive,
its Preferred Ratchet Rights and Warrant Ratchet Rights with
respect to such Subsequent Financing.

NOW, THEREFORE, in consideration of the
mutual agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows:

 

 

 

1. Waiver. Platinum Montaur, on behalf of itself
and each of its successors and assigns, hereby waives its Preferred
Ratchet Rights and Warrant Ratchet Rights with respect to the
Subsequent Financing; provided, however, that such waiver shall
be automatically revoked and of no further force and effect if the
Subsequent Financing is not completed by August 10,
2017.

2. Entire Agreement. This Waiver
contains the entire agreement among the parties hereto with respect
to the transactions contemplated hereby and supersedes all prior
arrangements or understandings, written or oral.

3. No Other Waiver. No waiver
granted hereunder shall be deemed to be a continuing waiver in the
future or a waiver of any other provisions, condition or
requirement of the Purchase Agreement or the Warrant, nor shall any
delay or omission of Platinum Montaur to exercise any right under
the Purchase Agreement or the Warrant in any manner impair the
exercise of any such right accruing to it thereafter.

4. Counterparts. This Waiver may
be executed in any number of counterparts by original or facsimile
signature, each such counterpart shall be an original instrument,
and all such counterparts together shall constitute one and the
same agreement.

5. Governing Law. This Waiver
shall be governed by and construed in accordance with the laws of
the State of New York. The terms of this Waiver applicable to
contracts made and to be performed wholly therein shall be governed
by and construed in accordance with the laws of the State of New
York (without regard to principles of conflicts of
laws).

[Signature page follows]

 

 

 

 

IN
WITNESS WHEREOF, the parties hereto have caused this Waiver to be
duly executed as of the date first above written.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

Platinum-Montaur Life Sciences, LLC 

 

	
 

	
 

	
 

	
 

	
By:

	
 

	
Matthew J.
Wright

	
 

	
 

	
 

	
 

	
Name:

	
 

	
Matthew J.
Wright

	
 

	
 

	
 

	
 

	
Title:

	
 

	
Company Manager, acting as
Joint Official Liquidator of Platinum Partners Value Arbitrage Fund
L.P. (the Joint Official Liquidators act as agents of the fund only
and contract without personal liability).

	
 

	

Acknowledged and
Agreed: 

 

FluoroPharma Medical, Inc.  

 

	
 

	
 

	
 

	
 

	
By:

Name:

Title:

	
  

	
/s/ Thomas Tulip

Thomas
Tulip

CEO and
President

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

 

[Signature
page to Waiver]ctmx-ex105c_888.htm

Exhibit 10.5(c)

Amended and Restated Severance and Change of Control Agreement

 

This Amended and Restated Severance and Change of Control Agreement (the “Agreement”) is made and entered into, effective as of October 3, 2016 (the “Effective Date”), by and between CytomX Therapeutics, Inc. a Delaware corporation (the “Company”), and Sean McCarthy, D. Phil. (“Employee”) and amends and restates in its entirety that certain Severance and Change of Control Agreement dated as of April 1, 2015 by and between the Company and Employee, as amended (the “Prior Agreement”).  

 

Upon acceptance of this Agreement, the following terms and conditions shall apply to your employment:

 

	
 
	
1.
	
Term of Employment and Severance Benefits. It is important for you to understand that California is an "at will" employment state. This means that you will have the right to terminate your employment relationship with the Company at any time for any reason. Similarly, the Company will have the right to terminate its employment relationship with you at any time for any reason. Your employment and this Agreement will be governed by the laws of California, without regard to the conflict of law rules thereof.  Notwithstanding the foregoing, in the event that, other than during a Change of Control Period (as defined below), the Company terminates your employment at any time without Cause (as defined below), or if you terminate your employment for Good Reason (as defined below), then the Company shall pay you a lump sum amount equal to (i) twelve (12) months of your then current base salary (without giving any effect to any reduction thereof which may constitute Good Reason), plus (ii) the annual bonus you are eligible to receive for the Calendar year in which your termination occurs assuming performance is achieved at target and pro-rated based on your termination date, which will be payable within thirty (30) days following your termination of employment.  In addition, the Company will provide and pay the premium cost for you and your dependents of medical and dental insurance benefits to the extent you were receiving such benefits immediately prior to your termination date from the date of your termination of employment through the earlier of the twelve (12) month anniversary of the termination of your employment, or the date you become eligible for medical and dental insurance benefits from a subsequent employer,  provided, that you timely elect "COBRA" coverage under the Company group health insurance plan under which coverage was being provided to you at the time when your employment terminates. If the Company is unable to provide such medical and dental insurance benefits or "COBRA" coverage is not available to you as of the time when your employment is terminated, then the Company will pay to you a lump sum equal to the premium cost of the benefits provided for the six months prior to your termination, payable within thirty (30) days following your termination of employment.  

 

	
 
	
2.
	
Change of Control.  In the event the Company consummates a Change of Control (as defined below) while you are employed by the Company, then the performance goals applicable to any performance-based equity awards held by you, including, without limitation any options to purchase the Company’s common stock that vest based upon the attainment of one or more performance goals, shall be deemed achieved in full as of immediately prior to the Change of Control.

 

	
 
	
3.
	
Termination in Connection with a Change of Control.  In the event that within sixty (60) days before or twelve (12) months following the consummation of a Change of Control (the “Change of Control 

1 | Page

 

 

 

Exhibit 10.5(c)

	
 
		
Period”), the Company, or any successor thereto, terminates your employment without Cause or you terminate your employment for Good Reason, then the Company shall (i) pay a lump sum amount equal to eighteen (18) months of your then current base salary (without giving any effect to any reduction thereof which may constitute Good Reason), which will be payable within thirty (30) days following your termination of employment, (ii) pay a lump sum amount equal to eighteen (18) months of the annual bonus you are eligible to receive for the current Calendar year assuming performance is achieved at target and, which will be payable within thirty (30) days following your termination of employment, and (iii) the vesting and, if applicable, exercisability of each Company equity award held by you, including, without limitation, each stock option of any kind and nature (e.g., time or performance based, etc.), shall accelerate in full as of immediately prior to your termination of employment. In addition, the Company will provide and pay the premium cost for you and your dependents of medical and dental insurance benefits to the extent you were receiving such benefits immediately prior to your termination date from the date of your termination of employment through the earlier of the eighteen (18) month anniversary of the termination of your employment or the date you become eligible for medical and dental insurance benefits from a subsequent employer, provided that you timely elect "COBRA" coverage under the Company group health insurance plan under which coverage was being provided to you at the time when your employment terminates. If the Company is unable to provide such medical and dental insurance benefits or "COBRA" coverage is not available to you as of the time when your employment is terminated, then the Company will pay to you a lump sum equal to the premium cost of the benefits provided for the nine months prior to your termination, payable within thirty (30) days following your termination of employment.

 

	
 
	
4.
	
Release. The Company's obligations to make such payments and provide such benefits shall be contingent upon your execution of a release in a form reasonably acceptable to the Company (the "Release") which Release must be signed and any applicable revocation period with respect thereto must have expired by the 30th day following your termination of employment.  The Release will not waive any of your rights, or obligations of the Company, regarding: (1) any right to indemnification and/or contribution, advancement or payment of related expenses you may have pursuant to the Company’s Bylaws, Articles of Incorporation, under any written indemnification or other agreement between the parties, and/or under applicable law; (2) any rights that you may have to insurance coverage under any directors and officers liability insurance, other insurance policies of the Company, COBRA or any similar state law; (3) any claims for worker’s compensation, state disability or unemployment insurance benefits, or any other claims that cannot be released as a matter of applicable law; (4)  rights to any vested benefits under any stock, compensation or other employee benefit plan of the Company; (5) any rights you may have as an existing shareholder of the Company; and (6) any claims arising after the effective date of the Release. Nothing in the Release or any other agreement between you and the Company will prohibit or prevent you from providing truthful testimony or otherwise responding accurately and fully to any question, inquiry or request for information or documents when required by legal process, subpoena, notice, court order or law (including, without limitation, in any criminal, civil, or regulatory proceeding or investigation), or as necessary in any action for enforcement or claimed breach of this Agreement or any other legal dispute with the Company.  If the Release has been signed and any applicable revocation period has expired prior to the 30th day following your termination of employment, then the severance payments above may be made on such earlier date; provided, however, that if the 30th day following your termination of employment occurs in the calendar year following the year of your termination date, then the payments shall not be made earlier than January 1 of such subsequent calendar year.

 

	
 
	
5.
	
Section 280G of the Code. 

 

2 | Page

 

 

 

Exhibit 10.5(c)

	
 
	
(a)
	
Notwithstanding anything in this Agreement to the contrary, if any payment, distribution, or other benefit provided by the Company to or for the benefit of you, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (collectively, the “Payments”), (x) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (y) but for this Section 5 would be subject to the excise tax imposed by Section 4999 of the Code or any similar or successor provision thereto (the “Excise Tax”), then the Payments shall be either: (i) delivered in full pursuant to the terms of this Agreement, or (ii) delivered to such lesser extent as would result in no portion of the payment being subject to the Excise Tax, as determined in accordance with Section 5(b).

 

	
 
	
(b)
	
The determination of whether Section 5(a)(i) or Section 5(a)(ii) shall be given effect shall be made by the Company on the basis of which of such clauses results in the receipt by you of the greater Net After-Tax Receipt (as defined herein) of the aggregate Payments. The term “Net After-Tax Receipt” shall mean the present value (as determined in accordance with Section 280G of the Code) of the payments net of all applicable federal, state and local income, employment, and other applicable taxes and the Excise Tax.

 

	
 
	
(c)
	
If Section 5(a)(ii) is given effect, the reduction shall be accomplished in accordance with Section 409A of the Code and the following: first by reducing, on a pro rata basis, cash Payments that are exempt from Section 409A of the Code; second by reducing, on a pro rata basis, other cash Payments; and third by forfeiting any equity-based awards that vest and become payable, starting with the most recent equity-based awards that vest, to the extent necessary to accomplish such reduction.

 

	
 
	
(d)
	
Unless the Company and Employee otherwise agree in writing, any determination required under this Section 5 shall be made by the Company’s independent accountants or compensation consultants (the “Third Party”), and all such determinations shall be conclusive, final and binding on the parties hereto. The Company and Employee shall furnish to the Third Party such information and documents as the Third Party may reasonably request in order to make a determination under this Section 5. The Company shall bear all fees and costs of the Third Party with respect to all determinations under or contemplated by this Section 5.

 

For purposes of this Agreement, a "Change of Control" shall mean the occurrence of any of the following events, provided that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change in the ownership of a substantial portion of the assets of the Company, as defined in Treasury Regulation §§ 1.409A-3(i)(5)(v), (vi), and (vii): (i) any merger or consolidation that results in the voting securities of the Company outstanding immediately prior thereto representing (either by remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) less than 50% of the combined voting power of the voting securities of the Company or such surviving or acquiring entity outstanding immediately after such merger or consolidation; (ii) any sale of all or substantially all of the assets of the Company; (iii) the complete liquidation or dissolution of the Company; or (iv) the acquisition of "beneficial ownership" (as defined in Rule 13d-3 under the Exchange Act) of securities of the Company representing 50% or more of the combined voting power of the Company's then outstanding securities (other than through a merger or consolidation or an acquisition of securities directly from The Company) by any "person," as such term is used in Sections 13(d) and 14(d) of the Exchange Act, or combination of persons, other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportion as their ownership of stock of the Company.

 

3 | Page

 

 

 

Exhibit 10.5(c)

For purposes of this Agreement, "Cause" shall mean a termination of your employment based upon a finding by a majority of the Board of Directors of the Company or its successor, acting in good faith and based on its reasonable belief at the time, that you (a) have refused to perform the explicitly stated or reasonably assigned lawful and material duties required by your position (other than by reason of a disability or analogous condition); (b) have committed or engaged in a material act of theft, embezzlement, dishonesty or fraud, a breach of confidentiality, an unauthorized disclosure or use of inside information, customer lists, trade secrets or other confidential information; (c) have breached a material fiduciary duty, or willfully and materially violated any other duty, law, rule, or regulation relating to the performance of your duties to the Company or material policy of the Company or its successor; (d) have been convicted of, or pled guilty or nolo contendere to, misdemeanor involving moral turpitude or a felony; (e) have willfully and materially breached any of the provisions of any agreement with the Company or its successor which causes material injury to the Company; (f) have willfully engaged in unfair competition with, or otherwise acted intentionally in a manner materially injurious to the reputation, business or assets of, the Company or its successor; or (g) have improperly induced a vendor or customer to break or terminate any material contract with the Company or its successor or induced a principal for whom the Company or its successor acts as agent to terminate such agency relationship.  “Cause” shall only exist if the Company first provides you with written notice of any claimed ground for Cause and an opportunity to cure such ground, if curable, for thirty (30) days.  For purposes of this Agreement, no act or failure to act on your part will be considered “willful” unless it is done, or omitted to be done, by you intentionally, not in good faith and without reasonable belief that the action or omission was in the best interest of the Company.

 

For purposes of this Agreement, "Good Reason" shall mean the occurrence of any of the following events or circumstances without your written consent:  (i) a material diminution in your base compensation; (ii) a material diminution in your authority, duties or responsibility; (iii) a material change in the principal geographic location at which you must perform services from South San Francisco, California; (iv) any requirement that you engage in any illegal conduct; or (v) a material breach by the Company of this Agreement or any other material written agreement between you and the Company.  

 

In order to establish a "Good Reason" for terminating employment, you must provide written notice to the Company of the existence of the condition giving rise to the Good Reason, which notice must be provided within 90 days of the initial existence of such condition, the Company must fail to cure the condition within 30 days thereafter, and your termination of employment must occur no later than 30 days following the expiration of that 30-day cure period.

 

All severance or change of control payments are intended to be exempt from or, if not, shall be made in full compliance with Section 409A and shall begin only upon the date of your "separation from service" (as defined below), which occurs on or after the date of termination of the employment relationship, and shall be subject to the rules set forth below.

 

(a) It is intended that each installment, if any, of the severance or change of control payments and benefits provided under this Agreement shall be treated as a separate "payment" for purposes of Section 409 A of the Internal Revenue Code and the guidance issued thereunder ("Section 409A"). Neither you nor the Company shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.

 

(b) If, as of the date of your "separation from service" from the Company, you are not a "specified employee" (within the meaning of Section 409A), then each installment, if any, of the severance or change of control payments and benefits shall be made on the dates and terms set forth in this Agreement.

 

4 | Page

 

 

 

Exhibit 10.5(c)

(c) If, as of the date of your "separation from service" from the Company, you are a "specified employee" (within the meaning of Section 409A), then:

 

(i) Each installment, if any, of the severance or change of control payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-l(b)(4) to the maximum extent permissible under Section 409A; and

 

(ii) Each installment, if any, of the severance or change of control payments and benefits due under this Agreement that is not described in paragraph (i) above and that would, absent this subsection, be paid within the six-month period following your "separation from service" from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, upon your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance or change of control payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation Section 1.409A-l(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which the separation from service occurs.

 

(d) The determination of whether and when your separation from service from the Company has occurred shall be made and in a manner consistent with and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h). Solely for purposes of this paragraph (d), "the Company" shall include all persons with whom the Company would be considered a single employer under Sections 414(b) and 414(c) of the Code.

 

(e) All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirement that (i) any  reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.

 

(e)If either you or the Company reasonably determines that any payment hereunder will violate Section 409A, you and the Company shall use best efforts to restructure the payment in a manner that is either exempt from or compliant with Section 409A.  You and the Company agree that they will execute any and all amendments to this Agreement as may be necessary to ensure compliance with the distribution provisions of Section 409A in an effort to avoid or minimize, to the extent allowable by law, the tax (and any interest or penalties thereon) associated with Section 409A.  If it is determined that a payment under this Agreement was (or may be) made in violation of Section 409A, the Company 

5 | Page

 

 

 

Exhibit 10.5(c)

will cooperate reasonably with any effort by you to mitigate the tax consequences of such violation, including cooperation with your participation in any IRS voluntary compliance program or other correction procedure under Section 409A that may be available to you.

 

 

This Agreement will be binding on the parties and their successors and assigns. The Company shall require any successors or assigns to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession or assignment had taken place.  The terms of this Agreement and all of your rights hereunder will inure to the benefit of, and be enforceable by, your personal representatives, executors, administrators, successors, heirs, distributes, devisees and legatees.

 

This Agreement shall be governed by and construed in accordance with California law, without regard to the conflict of law rules thereof.

 

If any provision of this Agreement is determined to be illegal or unenforceable, then the remainder of this Agreement nonetheless shall be fully enforceable and binding upon the parties hereto, and it is the intent of the parties that a court or arbitrator shall enforce the remainder of this Agreement to the maximum extent permitted by law. The prevailing party in any dispute concerning the interpretation or enforcement of this Agreement will be entitled to an award of his or its costs and reasonable attorneys' fees, in addition to any other eligible relief. 

 

This Agreement (a) represents our entire understanding regarding the subject matter hereof, and supersedes and replaces all prior and contemporaneous understandings regarding such subject matter, whether oral or written, including, without limitation, the Prior Agreement and (b) may not be modified or amended, except by a written instrument executed by you and by a duly authorized officer of the Company.  In the event of any conflict between any of the terms in this Agreement and the terms of any other agreement between you and the Company, the terms of this Agreement shall control.

 

ACCEPTANCE

 

The undersigned agrees to and accepts the terms and conditions set forth above.

 

 

 

______11/3/16__________________________/s/ Sean McCarthy_______________

	
Date
	
Sean McCarthy, D. Phil.

 

 

 

______11/3/16__    _____________________/s/ Cynthia J. Ladd_________________

	
Date
	
Cynthia J. Ladd, Senior Vice President and General Counsel

 

6 | Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]